Sutro Biopharma announces interim Phase 1 safety data for STRO-001
Sutro Biopharma announced encouraging interim safety data from an ongoing Phase 1 dose escalation clinical trial of its product candidate STRO-001, a novel, specific and homogeneous anti-CD74 antibody-drug conjugate, as a potential therapy for patients with B-cell malignancies. The interim data from the trial includes 21 patients and separate dosing cohorts for multiple myeloma and non-Hodgkin lymphoma, was presented at the 24th European Hematology Association Congress in Amsterdam. According to the company, the data also showed "encouraging" preliminary anti-tumor activity for the ADC, including one complete response and one partial response among a cohort of heavily pre-treated patients with DLBCL. Overall, STRO-001 was generally well-tolerated.